Posts Tagged ‘survodutide’
June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]
February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]
October 3, 2023 — It’s enough to make our heads spin. The incredible vibrancy in obesity research is on full display at the meeting of the European Association for the Study of Diabetes – EASD 2023 in Hamburg. Today, it starts with a bang. Successive presentations on multi-agonists for obesity are scheduled this afternoon at EASD. But the abstracts […]
June 24, 2023 — Suddenly at the ADA2023 meeting in San Diego, it seems the tides are rolling in to promise more options than ever before for treating obesity. By tides we mean all those drugs targeting the GLP-1 receptors. GLP-1 is shorthand for glucagon-like peptide 1. Most, but not all of these drugs making a splash in San […]